Merz Group Participates in the “Made for Germany” Initiative
The Merz Group has taken a significant step in reinforcing its commitment to Germany’s industrial and economic future by joining the “Made for Germany” initiative, a prominent alliance of 129 leading family-owned and industrial enterprises. This initiative is dedicated to advocating for improved economic conditions, fostering innovation, and strengthening Germany’s position as a globally competitive industrial hub. For Merz Group, a company with deep historical roots and an expanding global footprint, this move aligns closely with its long-term strategic vision of sustaining growth while contributing to the resilience of its home market.
Founded more than a century ago and headquartered in Frankfurt, the Merz Group has evolved into an internationally recognized healthcare company specializing in aesthetic medicine and neurological treatments. With a legacy spanning 118 years, the company remains family-owned and continues to emphasize long-term value creation, innovation, and responsible corporate governance. Its participation in the “Made for Germany” initiative underscores its broader commitment to ensuring that Germany remains a favorable environment for industrial investment, research, and manufacturing.
A central pillar of Merz’s forward-looking strategy is its substantial investment in domestic manufacturing capabilities. The company has announced plans to invest more than €100 million by 2028 to expand its production facility in Dessau. This initiative represents not only a significant capital commitment but also a strategic response to rapidly increasing global demand for its products, particularly neurotoxins used in both therapeutic and aesthetic applications.
The expansion of the Dessau facility is expected to enhance production capacity and technological capabilities, enabling Merz Group to better serve growing international markets. Demand for neurotoxins has surged in recent years, driven largely by increasing adoption in aesthetic procedures as well as broader clinical applications in neurology. Regions such as Asia and Latin America have emerged as key growth markets, where Merz has established a strong presence and is considered among the leading providers in aesthetic medicine.
At the Dessau site, the company manufactures a range of advanced products, including neurotoxins and hyaluronic acid-based dermal fillers. These products play a critical role in both medical and cosmetic treatments. Neurotoxins are widely used in neurological therapies to manage conditions such as muscle spasticity and certain movement disorders, as well as in aesthetic procedures to reduce the appearance of wrinkles. Merz Group markets these products through its specialized divisions, including Merz Therapeutics for medical applications and Merz Aesthetics for cosmetic treatments.
Hyaluronic acid-based fillers, also produced at the Dessau facility, are a cornerstone of modern aesthetic medicine. These products are commonly used for facial rejuvenation, offering minimally invasive solutions for wrinkle reduction and volume restoration. The growing popularity of such procedures globally has further fueled demand for Merz’s product portfolio, reinforcing the importance of scaling up production capabilities.
Leadership at Merz has emphasized the strategic importance of Germany in the company’s future trajectory. Philip Burchard, CEO of the Merz Group, highlighted the company’s enduring commitment to its home country, noting that Germany is not only the origin of the business but also a central component of its long-term strategy. He pointed to the company’s highly skilled workforce as a key driver of its success and reiterated the importance of continued investment in Germany as both a responsibility and a strategic necessity. Notably, the majority of Merz’s global workforce—more than 5,500 employees—is based in Germany, underscoring the country’s role as the company’s operational backbone.
From a governance perspective, the family ownership structure continues to shape Merz’s strategic decisions. Christian Baatz, shareholder and managing director of Merz Familien Holding, emphasized the importance of long-term thinking, a hallmark of family-owned enterprises. Now in its fifth generation of ownership, the Merz family remains deeply committed to sustaining and expanding its industrial presence in Germany. Baatz noted that ongoing investments in the Dessau production site reflect this commitment, while also highlighting the need for supportive and reliable policy frameworks.
Indeed, Merz’s participation in the “Made for Germany” initiative reflects a broader call from industry leaders for stable and innovation-friendly economic conditions. Companies within the initiative advocate for policies that encourage investment, reduce regulatory burdens, and support research and development. For Merz, such an environment is essential to maintaining its competitive edge in a highly dynamic and globalized healthcare market.
The company’s strategic investments and advocacy efforts come at a time when Germany, like many industrialized nations, faces increasing competition from emerging markets and evolving global supply chains. By expanding domestic production and engaging in collaborative initiatives, Merz aims to contribute to the resilience and competitiveness of Germany’s industrial sector.
In summary, the Merz Group’s decision to join the “Made for Germany” initiative and invest heavily in its Dessau facility reflects a dual commitment to global growth and domestic strength. Through sustained investment, innovation, and collaboration, the company is positioning itself not only as a leader in healthcare and aesthetics but also as a key contributor to Germany’s industrial future.
About the Merz Group
The Merz Group has been a family-owned company headquartered in Frankfurt am Main since 1908. The group comprises seven companies. The largest are Merz Aesthetics – one of the world’s leading providers in the field of aesthetic medicine – Merz Therapeutics – a pharmaceutical company focusing on neurological diseases – and Merz Lifecare, a provider of over-the-counter medical products with well-known brands such as tetesept, Merz Spezial, SOS, and Zirkulin. With this brand portfolio, Merz Lifecare is among the market leaders in German-speaking countries. Almost all companies within the Merz Group – especially Merz Therapeutics and Merz Lifecare – are headquartered in Frankfurt.
The Merz Group employs over 5,500 people worldwide and generated sales of over 2.2 billion euros in the past financial year.
About Made for Germany
The “Made for Germany” initiative is an alliance of 129 companies from various sectors, including medium-sized businesses, start-ups, international corporations, and investors, with the goal of strengthening Germany’s economic position. The member companies have announced investments of over €800 billion and more than 200 flagship projects by 2028.
In cooperation with the German Federal Government, the initiative develops concrete reform proposals in ten strategic areas, including digitalization, energy costs, and reducing bureaucracy, to promote Germany’s competitiveness and economic growth. Since its founding in July 2025, “Made for Germany” has been advocating for the accelerated implementation of structural reforms and contributing its ideas to the European political debate.
At the Hannover Messe, Made for Germany recently brought together representatives from Airbus, Deutsche Telekom, Siemens, SAP and Isar Aerospace with Chancellor Friedrich Merz and other government representatives to discuss the use of artificial intelligence for industry as part of the realignment of industrial policy.
Source Link:https://www.businesswire.com/
